Due to the complex network that drives KRAS tumors, combinatorial multi-targets/multi-pathways inhibitory approach may be necessary to modulate cell growth in patients with a KRAS MT NSCLC [26-30]. Here, KRAS is linked to non-small cell lung carcinoma.